Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer

NCT04073615 is registered in ClinicalTrials.gov with Elevar Therapeutics as lead sponsor.

NCT NCT04073615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04073615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer
Lead sponsor
Elevar Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
November 18, 2019
Completion date
May 31, 2023
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer